Melphalan and Delayed engraftment - a phase IV clinical study of FDA data

Summary:

Delayed engraftment is reported as a side effect among people who take Melphalan (melphalan), especially for people who are male, 50-59 old, have been taking the drug for < 1 month also take Lenalidomide, and have Multiple myeloma.

The phase IV clinical study analyzes which people have Delayed engraftment when taking Melphalan. It is created by eHealthMe based on reports of 20,050 people who have side effects when taking Melphalan from the FDA, and is updated regularly.

What is Melphalan?

Melphalan has active ingredients of melphalan. eHealthMe is studying from 20,052 Melphalan users. Check the latest studies of Melphalan.

What is Delayed engraftment?

Delayed engraftment is found to be associated with 19 drugs and 61 conditions by eHealthMe. Check the latest studies of Delayed engraftment.

On Jul, 16, 2026

20,050 people reported to have side effects when taking Melphalan.
Among them, 23 people (0.11%) have Delayed engraftment.

Could Melphalan cause Delayed engraftment?

Among these 23 people:

How long have people been on Melphalan when they have Delayed engraftment? *

What is the gender of people who have Delayed engraftment when taking Melphalan? *

female: 16.67 %
male: 83.33 %

What is the age of people who have Delayed engraftment when taking Melphalan? *

What are other drugs people take besides Melphalan? *

What are other side effects people have besides Delayed engraftment? *

Respiratory Tract Infection Fungal: 6 people, 26.09%
Thrombocytopenia (decrease of platelets in blood): 5 people, 21.74%
Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 4 people, 17.39%
Anaemia (lack of blood): 4 people, 17.39%
Diarrhea: 3 people, 13.04%
Febrile Neutropenia (fever with reduced white blood cells): 3 people, 13.04%
Fungal Infection: 3 people, 13.04%
Sepsis (a severe blood infection that can lead to organ failure and death): 2 people, 8.70%
Infection: 2 people, 8.70%
Death: 2 people, 8.70%

What are the existing conditions these people have? *

Multiple Myeloma (cancer of the plasma cells): 13 people, 56.52%
Haematopoietic Stem Cell Mobilisation: 5 people, 21.74%
Thrombocytopenia (decrease of platelets in blood): 2 people, 8.70%
Non-Hodgkin's Lymphoma (malignant (cancer) cells form in the lymph system): 2 people, 8.70%
Lymphoma (cancer that begins in immune system cells): 2 people, 8.70%
Bone Marrow Conditioning Regimen: 2 people, 8.70%
Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 2 people, 8.70%
Transplant Rejection (a transplant material is not worked): 1 person, 4.35%
Peripheral T-Cell Lymphoma Unspecified (peripheral t-cell cancer unspecified): 1 person, 4.35%
Chronic Graft Versus Host Disease (immune cells attack the host's body cells after transplant): 1 person, 4.35%

* Approximation only. Some reports may have incomplete information.

Do you take Melphalan and have Delayed engraftment?

- Check whether Delayed engraftment is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Melphalan:

Melphalan (20,052 reports)

Browse all side effects of Melphalan:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Delayed engraftment:

Delayed engraftment (19 drugs)

Browse all the conditions that are associated with Delayed engraftment:

Delayed engraftment (61 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on melphalan (the active ingredients of Melphalan) and Melphalan (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.